Let us help you enhance your success in fighting NASH
NASH (non-alcoholic Steatohepatitis) is the most severe form of NAFLD (non-alcoholic fatty liver disease). NASH, being a ‘silent’, yet chronic disease, the pathology remains poorly known and underdiagnosed. Almost 12% of people living in developed countries are suffering from NASH. With a growing number of patients developing NASH-related end-stage liver disease, and no registered treatment yet for NASH, there is an urgent need to develop therapeutic agents for NASH. At Barc Lab, we have made it our mission to support all clinical research to stop this silent killer and to assist in searching for a better diagnosis and treatment. That is why we have been a benefactor and supporter of the first International NASH day, organized on June 12th, 2018.
The current golden standard for diagnosis of NASH is still performing a liver biopsy. At Barc Lab we can routinely process, stain and interpret these liver biopsies by working together with a network of liver pathologists all over the world.
Next to processing and reading of liver biopsies, Barc Lab can assist with testing for several other liver markers and can include calculations for non-invasive fibrosis scores:
- Markers that can indicate possible genetic predisposition:
- miRNA such as miR21 and miR122
- Liver biomarkers:
- CK18 M30 & M65
- FGF-19 and FGF-21
- Hyaluronic acid, PIIINP and TIMP-1
- Inflammation markers
- Glycemic and lipid markers:
- Aplipoprotein A2, C3 and E
- Non-invasive scores of fibrosis, such as FIB-4 index, ELF, Fibrotest, Steatotest, MELD score, etc.
Currently Barc Lab is acting as the central lab for the biggest phase 3 study in NASH so far, with now over 1,300 patients randomized and over 200,000 samples received and analyzed.
Watch the video below on the 1st International NASH Day, which Barc Lab has proudly supported.